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Abstract
Donor human leukocyte antigen (HLA)-specific antibod-
ies (DSA) play an important role in solid organ trans-
plantation. Preexisting IgG isotype DSA are considered 
a risk factor for antibody mediated rejection, graft 
failure or graft loss. The post-transplant development 
of DSA depends on multiple factors including immuno-
genicity of mismatched antigens, HLA class Ⅱ typing of 
the recipient, cytokine gene polymorphisms, and cellu-
lar immunoregulatory mechanisms. De novo  developed 
antibodies require special attention because not all DSA 
have equal clinical significance. Therefore, it is impor-
tant for transplant clinicians and transplant immunolo-
gists to accurately characterize DSA. In this review, the 
contemporary immunological techniques for detection 
and characterization of anti-HLA antibodies and their 
pitfalls are described.
© 2014 Baishideng Publishing Group Inc. All rights reserved.
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Core tip: In solid organ transplantations the graft 
outcomes critically depend on the degree of human 
leukocyte antigen (HLA) matching between the donor 
and recipient. Although the cellular component of the 
allogeneic immune response to the transplanted tissue 
plays a key role, the contribution of antibodies should 
not be underestimated. The detection of anti-HLA 
class Ⅰ and class Ⅱ antibodies is an important com-
ponent of the initial work-up of a potential transplant 
candidate. The introduction of new highly sensitive 
technologies such as solid-phase based technologies 
has had a tremendous effect on organ allocation and 
immunomodulation strategies.
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INTRODUCTION
In most cases the development of  alloantibodies against 
human leukocyte antigens (HLAs) is related to immu-
nization via blood and/or blood product transfusions, 
pregnancy, and transplants. There are scattered reports 
in the literature indicating the production of  HLA anti-
bodies may be elicited by vaccinations and infections due 
to cross reactivity between viral/bacterial antigens and 
HLAs[1-4] or through the bystander effect[5-8]. Humoral 
or antibody-mediated immunity requires noncovalent 
contact between antigens and antibodies. The hyper 
variable regions of  the light and heavy immunoglobulin 
chains are termed complementarity-determining regions 
and they are primarily involved in the interaction with 
antigens. Antibody effector functions are specified by 
the constant domains of  the heavy chains. The most 
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important function of  these domains is the activation of  
the complement cascade, which is triggered by confor-
mational changes in the hinge area after antigen binding. 
Complement activation results in the destruction of  the 
cell membrane.
In solid organ transplantations of  the kidney, heart, 
lung, and pancreas graft outcomes critically depend on 
the degree of  HLA matching between the donor and 
recipient[9-17]. The cellular components of  the allogeneic 
immune response to the transplanted tissue play a key 
role in this matching and the contribution of  antibodies 
should not be underestimated[18-22]. The detection of  anti-
HLA class Ⅰ and class Ⅱ antibodies is an important com-
ponent of  the initial work-up of  a potential transplant 
candidate (TC). The rationale for obtaining this informa-
tion is related to clinical studies, which have universally 
demonstrated that pre-existing donor specific antibodies 
(DSAs) represent a significant risk factor for graft out-
come[23-34]. The importance of  the post-transplant moni-
toring of  DSAs in kidney and cardiac transplants has 
been widely described[35-45]. The de novo development of  
DSAs strictly depends on the antigenicity and immuno-
genicity of  mismatched HLAs. The substantial influence 
on antibody production involves other factors such as 
the HLA class Ⅱ type of  the responder, immunosup-
pressive medications, cytokine and chemokine genomic 
polymorphisms, and the hormonal background of  the 
recipient[11,45-50].
It is generally accepted that de novo developed DSAs 
represent a risk factor for graft failure even at low con-
centrations. The early detection of  DSAs considerably 
reduces the incidence of  antibody-mediated rejection 
(AMR) and transplant glomerulopathy[23,51-58]. A post-
transplant antibody analysis is a part of  the routine moni-
toring of  recipients. The introduction of  new highly sen-
sitive technologies such as solid-phase based technologies 
has had a tremendous effect on the clinical approach to 
anti-HLA antibody analysis[56-58]. The purpose of  this 
review is to familiarize the reader with the methodologi-
cal aspects and pitfalls of  anti-HLA antibody analysis in 
solid-organ TC. Solid phase (SP) techniques will be spe-
cifically addressed.
METHODS OF ANTIBODY 
IDENTIFICATION
Cell based assays
Complement-dependent cytotoxicity: The long-
established NIH complement-dependent cytotoxicity 
(CDC) method and its modifications are still widely 
used[59-64]. This assay allows the identification of  high con-
centrations of  antibodies to HLAs. There are two main 
purposes for applying the CDC method. This method 
can be used to estimate the percent of  reactive antibod-
ies (PRA) when the recipient serum is incubated with a 
panel of  HLA typed T- or B-lymphocytes. If  the serum 
contains antibodies against a particular HLA then the 
addition of  rabbit complement causes cell death that is 
visualized by staining and microscopic examination. This 
test is also used for the cross-matching (CM) or detec-
tion of  complement binding antibodies against the HLAs 
of  a particular donor. Various modifications of  the NIH 
CDC method including extended incubation, additional 
washings, and the addition of  secondary antihuman light 
kappa chain specific antibodies have been used to increase 
the sensitivity of  the assay. Notably, the NIH CDC assay 
detects anti-HLA antibodies of  the IgG and IgM isotypes. 
However, the IgM isotype has considerably less clinical 
significance[20,64-68]. Donors with HLA recipient antibodies 
detected by CDC should be avoided due to the high risk 
of  hyperacute or delayed hyperacute rejection. Currently, 
this assay is primarily used to determine the efficacies of  
the desensitization or immunomodulation of  recipients 
with high concentrations of  anti-HLAs and identify re-
cipients that are CDC-CM positive for their donors. Nu-
merous reports have demonstrated that changing CDC-
CM from positive to negative via durable DSA removal 
significantly reduces the risk of  graft loss. The short-term 
graft survival in such recipients is not significantly differ-
ent from recipients without CDC-positive DSA[69-75]. 
In the early 1970s, Patel et al[76] reported a consider-
able rate of  graft failure in recipients who were CDC-CM 
negative with their donors. These observations indicated 
that the sensitivities of  the CDC assay and its modifica-
tions were insufficient to detect low concentrations of  
DSA and was deleterious for the transplanted organ. 
Methods for increasing the sensitivity of  antibody detec-
tion by flow cytometry (FC) based techniques were intro-
duced more than 30 years ago[77].
Flow cytometry methods
Although FC methods of  analysis are more sensitive 
than the CDC method they are subject to the effects of  
non-HLA and autologous antibodies that complicate the 
interpretation of  the results. This complication is par-
ticularly important in the case of  B-lymphocytes because 
they express Fc receptors and various adhesion molecules 
on their surfaces that facilitate non-specific binding[67,78]. 
B-cell false positive FC CM results may erroneously pre-
clude transplants that should have favorable outcomes. 
The non-specific antibody binding may be reduced by 
the incubation of  the lymphocytes with pronase, enzyme 
destroying Fc receptors, and other members of  the Ig 
superfamily[79-82]. FC cell-based assays can also be used 
for PRA analysis. In this case, pooled HLA-typed lym-
phocytes are incubated with the recipient serum, and the 
percentage of  positively reactive cells is determined based 
on the median channel shift[83]. This method has limited 
applicability because further testing is required to deter-
mine the antibody specificity. Additionally, the absorption 
of  anti-HLA class Ⅰ is required when class Ⅱ PRA is 
analyzed.
SOLID PHASE ASSAYS
SP technologies use purified HLA class Ⅰ and/or class 
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Ⅱ proteins that are attached to an artificial substrate or 
matrix. These assays offer significantly higher sensitivities 
and specificities than cellular methods[84-86]. 
Enzyme-linked immunosorbent assay
Enzyme-linked immunosorbent assay (ELISA) was the 
first solid-phase analysis developed for antibody screen-
ing and specificity determination[87]. In this assay, HLA 
molecules are bound to the wells of  plastic plates and 
positive reactions are measured by the color signal inten-
sity produced by enzymes conjugated to anti-human an-
tibodies following the addition of  substrate to the wells. 
Purified pooled HLA-Ⅰ and -Ⅱ molecules bound to the 
wells are used for antibody screening/detection and PRA 
analysis. To define the antibody specificity, HLA proteins 
isolated from one individual are used to coat each well of  
the plate.
FC
FC SP assays use microspheres that have been coated 
with soluble HLA proteins that are extracted from a 
single cell line for specificity analysis or mixed for PRA 
analysis (FlowPRA Specific, FlowPRA, One Lambda)[88]. 
After the addition of  the fluorescence-conjugated anti-
human secondary antibodies a light signal is generated 
that indicates a positive binding of  the antibody to HLA 
molecule(s). As with ELISA, this method can be designed 
to detect antibodies of  IgG and IgM isotypes depending 
on the specificity of  the secondary antibodies[84,89,90].
Luminex
Luminex-based technology has revolutionized the ap-
proach to anti-HLA antibody analysis and resolved 
ambiguities associated with the interpretation of  CDC 
and FC results. This highly sensitive methodology has be-
come an integral component of  clinical decision-making 
and pathological diagnosis of  transplanted organ injury. 
Luminex technology also incorporates microparticles 
(beads) that have been conjugated to varying amounts 
of  two dyes, which enable the identification of  100 sets 
of  beads. HLA-specific alloantibodies are detected via 
the addition to a reaction mixture of  secondary phyco-
erythrin (PE)-conjugated anti-human antibodies. Each 
group of  beads can be identified by the amount of  con-
jugated fluorochromes and it is possible to identify which 
HLAs have bound antibodies. The light signal produced 
by bound antibody is proportional to its concentration 
and is expressed as the mean fluorescence intensity (MFI). 
The original assay was introduced as a combination of  
beads that were coated with HLA proteins extracted 
from individual cells. More recently, Luminex technol-
ogy introduced a modification of  the assay that included 
beads coated with a single class Ⅰ or class Ⅱ HLA. This 
methodological approach significantly improved antibody 
specificity analyses, particularly in highly sensitized pa-
tients[88,91-95]. The considerably higher surface density of  
HLAs on the microbeads compared to that on lympho-
cytes makes the Luminex single-antigen (SA) methodol-
ogy extremely specific and highly sensitive. As a result, 
investigators can detect very low concentrations of  HLA-
directed antibodies. In the last decade, numerous reports 
have addressed the methodological aspects, clinical rel-
evance, and standardization of  the Luminex SP SA assay 
for the detection of  antibodies[53,54,95-100]. The results of  
these studies have significantly expanded our understand-
ing of  anti-HLA antibody biology and the mechanism of  
the interaction between antibodies with antigens. This in-
creased understanding includes improved information on 
isotypes and subtypes of  antibodies, their abilities to bind 
complement, and fine epitope specificity. Fine epitope 
specificity is particularly important for the prediction of  
graft rejection[93,101-103]. There are also many new questions 
such as how does the signal produced by the DSAs de-
tected in the SA Luminex assay correlate with positive FC 
CM, what is the clinical relevance of  minimally reactive 
DSA, and how can the bead saturation effect be identi-
fied and overcome. Additionally, there are many other 
questions to address.
In this review, I describe the pitfalls, caveats, and limi-
tations of  the Luminex SP SA assay based on seven years 
of  experience and clinical outcomes/observations at our 
transplant center. 
Luminex SA SP assay: Technical challenges
Correlation of  DSA MFI values with the results of  FC 
CM tests: It is generally accepted that preexisting DSA 
directed against HLA can cause allograft injury or loss. 
FC CM is the most sensitive immunological method and 
it allows for the detection of  DSA in TC serum. Positive 
FC CM is associated with an elevated risk of  AMR[12,16,
17,21,32,104-107]. The accurate detection of  the spectrum of  
anti-HLA antibodies is critical for organ allocation and 
the prediction of  FC CM results. Comparisons of  the 
antibody profiles in the sera of  TCs with the HLA typing 
of  the potential donors are called virtual cross matches 
(VCMs). VCMs are particularly important in cases of  
heart and lung allocation in which the cold ischemia time 
is limited. VCM has been widely used at our transplant 
center for several years. Although SP Luminex technol-
ogy allows for the very specific detection of  DSAs at 
relatively low concentrations, issues regarding how strong 
the DSAs must be to cause positive FC CM results have 
to be addressed. The results of  a multicenter study per-
formed by Reed et al[89] suggested optimal cutoffs from 
1000 to 1500 MFIs for antibodies to the HLA-A, -B, 
-DRB1, and -DQB1 loci. DSAs with MFIs within the in-
dicated range are considered weak, and those below this 
range are considered negative. The correlation analyses 
between MFI values of  DSAs and the results of  FC CM 
assays performed in our laboratory have demonstrated 
that MFIs ≥ 2600 produced by anti-HLA Ⅰ antibodies 
(HLA-A and -B loci) most likely result in T cell-positive 
FC CM results (positive predictive value 97%). Further-
more, MFIs ≥ 3100 produced by anti-HLA Ⅱ antibod-
ies (HLA-DRB1 and -DQB1 loci) most likely generate 
B cell-positive FC CM results (positive predictive value 
155 September 24, 2014|Volume 4|Issue 3|WJT|www.wjgnet.com
Lobashevsky AL. Methodological aspects of anti-HLA antibody analysis
95%, R = 0.78)[93] (Figures 1 and 2). The positive cutoffs 
determined in this assay also predict positive FC CM re-
sults when the recipient has multi-specific DSAs.
Quantities of HLA proteins on the beads 
The density of  the HLA molecules on the beads is sig-
nificantly higher than that on lymphocytes (5 × 104-105 
molecules per cell) or endothelial cells. Therefore, even a 
minor admixture of  anti-HLA antibodies or anti-idiotypic 
antibodies of  the IgM isotype may cause false negative 
results. To overcome this obstacle, serum Dithiothreitol 
(DTT)-treatment is recommended[108-110].
We have observed strong positive T cell FC CM 
results and weakly reactive DSAs to HLA-B8 by SA Lu-
minex. Subsequent DTT treatment of  the serum resolved 
this discrepancy and revealed DSAs to the antigen with 
MFI values of  24000 (Table 1).
Denatured HLA and cryptic epitopes
Discrepancies between negative FC CM results and 
strongly reactive DSAs are observed when biochemical 
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Figure 2  Correlation analysis between mean fluorescence intensity of 
anti-human leukocyte antigen class Ⅰ antibodies and T cell flow cytometry 
cross match median channel shift. Each blue diamond represents a single 
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Table 1  Donor specific antibodies solid phase single-antigen 
Luminex analysis in unmodified and Dithiothreitol treated 
serum
Serum treatment HLA specificities
B8 B18 DR53
DDT treated    247771 23500 23100
Untreated       550   1764   4852
1The numbers in the table indicate MFI values. HLA: Human leukocyte 
antigen; MFI: Mean fluorescence intensity; DDT: Dithiothreitol.
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higher affinities for DSAs and when present in large 
amounts they produce strong false positive signals. An 
acid treatment is used to exclude antibodies against dena-
tured HLAs. Antibodies against denatured HLA-B55 and 
HLA-B54 proteins are likely present when no differences 
or increased MFI values are observed between treated 
and untreated beads[110-113] (Figure 3). The acid treatment 
procedure is ineffective when analyzing anti-class Ⅱ an-
tibodies. In these types of  situations, Luminex screening 
tests or Luminex class Ⅱ phenotypic bead assays are per-
formed.
Uneven bead distributions on SA Luminex dot blot 
histograms
Strong DSAs to HLA-C2 in the recipient serum have 
been shown to yield negative FC CM results[114] (Figure 
4). To investigate this discrepancy, we analyzed the bead 
counts and bead distributions on the SA dot blot histo-
grams of  the aforementioned bead sets. Figure 4A shows 
the MFI values of  13100 for the anti-HLA-C2 antibodies 
and an uneven bead distribution. As shown in the figure, 
a majority of  the beads are located within the negative 
MFI range and only a few have MFI values of  approxi-
mately 30000. These findings indicate that the MFIs 
observed on SA antibody panels represent an average 
number between the lowest and highest values. A repeat 
of  the assay confirmed the absence of  DSAs, and the SA 
dot blot C2 histogram formed single clusters of  beads 
located in the negative area (Figure 4B).
Non-specific antibody reactivity
One of  the limitations of  SA SP Luminex technology de-
tailed in the literature is non-specific reactivity[90,106]. The 
main reasons for high background levels may be related 
to antibodies reacting to latex, autoimmune disease(s), 
and some medications (IVIG)[75,115-117]. Non-specific an-
tibody binding complicates antibody analysis due to the 
appearance of  multiple false positive antibodies and may 
affect organ allocation and the interpretation of  VCM 
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modification (denaturing) of  HLA proteins during the 
bead conjugation process occurs. Denatured HLAs have 
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negative control (MFI > 100) usually indicate high back-
ground and require the test to be repeated. However, if  
serum samples taken at different time points consistently 
exhibit elevated non-specific reactivity after adsorption 
then antibody analysis can be performed appropriately[118]. 
An unusual anti-class Ⅱ antibody profile was observed in 
one kidney TC. The serum of  this patient contained pan-
reactive anti-DRB1 antibodies including self-specificities 
(Figure 7; the self-antigens are circled in red). A subse-
quent autologous FC CM assay was B cell positive and 
Luminex SP screening PRA analysis did not detect any 
antibodies. The results of  these tests led to the conclu-
sion that the anti-DRB1 antibodies in the serum of  this 
TC serum were clinically irrelevant.
Bead oversaturation
The sera from patients may contain strong high-titer an-
tibodies that can cause a prozoning or oversaturation ef-
fect. Figure 8 shows the oversaturation of  SA beads with 
antibodies to HLA-I. In our experience this phenomenon 
is suspected when the MFI values exceed 20000. As 
shown in Figure 8, the antibodies against A2, A69, B51, 
and B52 exhibited oversaturation that disappeared upon 
the dilution of  the serum. This prozoning effect has been 
reported by others with the SA Luminex bead assay[119-123]. 
Dilution of  the serum to exclude the oversaturation of  
antibodies is critical when the antibody analysis is per-
formed on the sera of  highly sensitized TCs who have 
been subjected to immunomodulation/desensitization. 
component 1q SA SP binding assay 
The classical pathway of  complement activation follow-
ing antibody/HLA interactions is usually associated with 
graft cell damage and poor outcomes. Over the last de-
cade it has been demonstrated that some of  the DSAs 
detected with SA SP analysis but not with CDC (FC pos/
CDC neg) can activate the complement system[124-128]. 
Numerous studies have demonstrated that inferior graft 
outcomes, graft loss, and C4d deposition are observed 
more frequently among recipients with DSAs that bind 
complement component 1 (C1q)[129-135]. The recently 
developed C1q SA SP assay (C1qScreen™) represents a 
reliable tool for distinguishing the binding IgG antibody 
from the complement-fixing antibodies of  the IgG and 
IgM isotypes. The complement-fixing antibodies (C1q+) 
are detected using external C1q and anti-C1q antibod-
ies conjugated to PE. The fluorescence intensity of  the 
signal is proportional to the amount of  bound C1q and is 
measured by MFI. The presence of  C1q+ DSA is more 
strongly correlated with graft failure than the presence 
of  antibodies that do not bind complement[126,136-139]. 
However, the absence of  complement fixing antibodies 
has recently been reported in recipients with documented 
AMR. This result may indicate a low sensitivity of  the 
C1q assay. The elegant studies of  R. Liwski have dem-
onstrated a good relationship between the anti-human 
globulin (AHG)-C1qScreen™ assay and CDC-AHG 
reactivity[128,129]. This highly sensitive modification of  the 
original C1qScreen™ protocol would certainly be useful 
for risk assessment.
SA SP Luminex-based methodology and structural 
analysis of HLA epitopes
Each HLA protein represents a linear sequence of  amino 
acid residues (AAR) or triplets, and the degree of  mis-
match is assessed as the number of  triplets that are not 
shared between the donor and the recipient. There are 
two important points regarding this approach. First, only 
the AARs accessible to antibodies that reside in α-helical 
coils and β-loops are considered. In contrast, the triplets 
that are located in the β-pleated floor and beneath the 
α-chains are not available for antibody binding and are 
often not critical for antibody production because they 
are not immunogenic[140-143]. Second, alloantibodies can be 
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produced only against non-self-mismatched triplets. 
Furthermore, AAR triplet analysis (HLA Matchmaker 
computer algorithm) can explain or predict the develop-
ment of  post-transplant antibodies in kidney allograft re-
cipients[46,50]. Subsequent analyses of  patients’ antibodies 
and HLA-specific monoclonal antibodies have revealed 
that each HLA consists of  structurally defined “eplets” 
that represent epitopes comprised of  the AARs within a 
3 Å-5 Å radius of  the surface of  the molecule[48,10,122]. An 
example of  such analysis is presented in Figure 9, Figure 
10 and Table 2. The HLA typing results of  the recipient, 
previous donors, and current donors are given in Table 3. 
The pre-transplant evaluation of  the second kidney TC 
revealed multiple weakly reactive (MFI cutoff  ≥ 2600) 
antibodies including DSA B*44:02 (Figure 9) and strong-
ly positive T cell FC CM results (∆MCS = 129, positive 
cutoff  = 50) (the autologous T cell FC CM results ap-
peared to be negative). A HLAMatchmaker analysis of  
the HLA-B locus-specific antibodies determined that the 
antibody reactivity was restricted to two epitopes/eplets 
44re and 167es on the immunizing HLA-B*45:01antigen. 
FC CM and SA bead assays revealed that the antigens 
targeted by the recipient antibodies shared the eplet pair 
44re69at. Eplets that were mismatched with the immu-
nizer were 44re and 167es, while 69at was shared by both 
161 September 24, 2014|Volume 4|Issue 3|WJT|www.wjgnet.com
M
FI
A11
A2
A30
A31
A69
B51
B52
C10
C9
Antibody specificity 
in the serum
25000
20000
15000
10000
5000
0
1:512  1:256  1:128   1:64   1:32    1:16    1:4     neat
Serum dilutions
Figure 8  Phenomenon of class I bead oversaturation with antibodies. Y 
axis indicates MFI values, X axis indicates serum dilution. Ten percent fetal 
bovine serum in roswell park memorial institute medium was used as diluents. 
MFI: Mean fluorescence intensity.
Figure 9  Anti-Class Ⅰ antibodies detected in the serum of kidney transplant candidate C. The numbers in blue circles indicate HLA specificities mismatched 
with the 1st donor. The number in red circle indicates HLA specificity mismatched with the current donor; the numbers in parenthesis indicate allelic assignment of 
HLA. Y axis indicates MFI values, X axis indicates bead number and HLA-A and -B loci specificities. Colored bars represent MFI values of different intensity: Green < 
500; blue 501-1600; brown 1601-2500; red > 2500. HLA: Human leukocyte antigen; MFI: Mean fluorescence intensity.
M
FI
14490
12880
11270
9660
8050
6440
4830
3220
1610
7    35    34    59    58   43    79   48   80    71   57    70    56    76   89    16    88    773
HLA class Ⅰ proteins attached to the beads
7327(07:02)
67425544568227817644 (44:02)
4578
67
A
B
Cw
Table 3  Human leukocyte antigen Class Ⅰ typing results of 
the recipient and previous and current donors
A locus B locus C locus
Recipient 23:01 66:01 41:01 49:01 07:01 17:01
1st donor (immunizer)  03:01a 26:01 07:02 45:01 06:02 07:01
Current donor 23:01 24:01 44:02 49:01 03:03 07:01
aMismatched alleles are given in bold font.
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Figure 10  Three dimensional map of mismatched and shared eplets. Alpha 
chain domains are in purple; peptide in the antigen presenting groove is in 
brown color; eplets are in yellow; black transparent circle specifies the patch 
comprising two eplets.
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the donor’s B7 and the patient’s A23 and A66 (Figure 10).
The identification of  immunogenic epitopes sig-
nificantly affects the prediction of  post-transplant al-
loantibody specificities, donor selection, graft outcome, 
and organ allocation. The recent studies of  Zeevi et al[142] 
and Duquesnoy et al[143] used monoclonal antibodies to 
demonstrate the anti-HLA antibody complement-fixing 
abilities strictly depend on the configuration of  the criti-
cal contact eplet(s)[140,141]. The results of  their studies 
indicated that complete complement cascade activation is 
determined by the energy produced from the antibody-
HLA interaction. The amount of  this energy should 
be sufficient to induce conformational changes of  the 
constant region of  the antibody to elicit C1q binding and 
subsequent component activation. The authors hypoth-
esized that the binding energies of  the SA C1q-negative 
antibodies are insufficient to induce conformational 
changes in the constant region. However, in the cases of  
the C1q+ and CDC+ antibodies this energy is sufficient 
to trigger complete complement activation and cell mem-
brane damage[141,143].
CONCLUSION
The identification of  anti-HLA antibodies in TC serum 
is a major task of  HLA laboratories and transplant physi-
cians and is important for graft failure risk assessment 
and donor selection. Furthermore, antibody detection is 
critical in highly sensitized TCs who have been subjected 
to desensitization (immunomodulation). SA SP analysis is 
a highly sensitive and highly specific method of  antibody 
characterization that enables the detection of  low con-
centrations of  antibodies and their fine HLA specificities. 
However, this assay is not free from limitations includ-
ing large variation in the numbers of  HLA molecules 
per bead and the effects of  manual (i.e., technologist-to-
technologist) factors on assay variance. In this review, I 
attempted to share multiple years of  experience perform-
ing SA SP assays for pre- and post-transplant antibody 
analyses in my laboratory and address some pitfalls and 
caveats of  this assay. Evaluations of  the clinical signifi-
cance of  anti-HLA antibodies should undeniably include 
their concentrations, isotypes, ability to fix the comple-
ment, and fine epitope specificity.
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